Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Os efeitos do estresse operacional repetido e da recuperação limitada na capacidade de resiliência (REP DEF)

This longitudinal study will examine the effects of repeated bouts of operational stress and limited recovery on integrated MPS, whole-body protein balance, iron absorption, and aerobic performance. Following baseline characterization measures, active adults (n=24) representative of normal weight phenotype (NW; n=12) and overweight phenotype (OW; n=12) will complete a 48h balance phase preceding two rounds of repeated 72h energy deficit exposure each immediately followed by a 48h recovery phase. NW cutoff will be defined ≤ 22% body fat for males and ≤ 32% body fat for females. OW cutoff will be defined as >22% body fat for males and >32% body fat for females. These body composition cutoffs are informed by the maximum allowable percent body fat standards outlined in current Army Regulation 600-9. Additional details for determining % body fat are outlined in the experimental procedures section of the protocol.

Visão geral do estudo

Descrição detalhada

Operational stress inherent of military training and operations is largely unavoidable and jeopardizes Warfighter readiness and performance. Operational stressors, including high physical activity, severe energy deficiency, and restricted sleep, challenge Warfighter resilience. The characterization of physiological factors contributing to maintained or declining resilience during repeated stress exposures with limited recovery is therefore required to enable development of new, targeted interventions that maintain or enhance resilience. Previous efforts have characterized the regulation of physiological status, including muscle recovery and endocrine function, during operational stress. However, no studies have directly assessed the effects of limited recovery (i.e., 48h) on physiological and performance decrements associated with repeated operational stress or resilience capacity. It is possible that repeated missions and limited recovery will drive progressive declines of physiological status and performance. The effects of operational stress on nutrition status also negatively impact readiness and performance. Absorption of key dietary nutrients, such as iron, is required to sustain nutritional status; and iron status, specifically, has been associated with performance declines. Laboratory and field-based studies from our group have shown declines in iron status and absorption following a single simulated sustained operation. However, no studies have directly assessed the effects of limited recovery (i.e., 48h) on physiological and performance decrements associated with repeated operational stress or resilience capacity. It is possible that repeated missions and limited recovery will drive progressive declines of physiological status and performance. Beyond characterizing the effects of repeated cycles of operational stress, there is potential value in determining whether body composition phenotypes (i.e., "energy deficiency-sensitive" and "energy deficiency-resistant") may modulate resilience during energy deficiency. Should phenotype-based differences be determined and suggest more beneficial/resilient vs. less beneficial/less resilient body composition phenotypes, guidance to maintain or interventions to achieve optimal body composition are potential individualized strategies to enhance resilience.

This longitudinal study will examine the effects of repeated operational stress and limited recovery on integrated muscle protein synthesis, whole-body protein balance, iron absorption, and aerobic performance. Adults (n=24) representative of normal weight and overweight phenotype (n=12/phenotype) will complete a 48h balance phase preceding two repeated rounds of 72h energy deficit (increased physical activity and reduced dietary intake) with sleep restriction followed by a 48h recovery phase.

Tipo de estudo

Intervencional

Inscrição (Real)

27

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Massachusetts
      • Natick, Massachusetts, Estados Unidos, 01760
        • US Army Research Institute of Environmental Medicine

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

17 anos a 39 anos (Filho, Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Men and women aged 18 - 39 years (17 - 39 years if military personnel)
  • Weight stable in the past 2 months (± approximately 5 kg)
  • Healthy without evidence of chronic illness or musculoskeletal injury as determined by the USARIEM Office of Medical Support and Oversight (OMSO) or home duty station medical support (HMS)
  • Functional exercise (i.e., step ups, box jumps, body mass movements) and/or aerobic exercise trained defined by self-report as performing ≥ 2 sessions/wk for previous 6 months
  • Willing to refrain from alcohol, smoking any nicotine product (includes e-cigarettes); vaping, chewing tobacco, caffeine not provided in the study, and dietary supplement use throughout the dietary interventions
  • Biological females must be on sustained (i.e., approximately >3 months) oral/hormonal contraceptive use which acts to maintain continuous hormonal levels (i.e., contains low-dose estrogen/progesterone with no oral placebos, hormonal IUD)
  • Supervisor approval for federal civilian employees and non-HRV active duty military personnel)

Exclusion Criteria:

  • Musculoskeletal injuries that compromise exercise capability as determined by OMSO or HMS
  • Metabolic or cardiovascular abnormalities, sleep disorders (i.e., sleep apnea) gastrointestinal disorders (e.g., kidney disease, diabetes, cardiovascular disease, etc.) as determined by OMSO or HMS
  • Abnormal or problems with blood clotting as determined by OMSO or HMS
  • History of complications with lidocaine or similar local anesthetic analogue
  • Present condition of alcoholism, anabolic steroids, or other substance abuse issues
  • Blood donation within 8-wk of beginning or completing study blood draws
  • Current diagnosis of Anemia (hemoglobin < 13 g/dL for males, hemoglobin < 12 g/dL for females) and Sickle Cell Anemia/Trait as determined by OMSO or HMS
  • Pregnant, trying to become pregnant, and/or breastfeeding (results of urine pregnancy test or self-report for breastfeeding will be obtained before body composition testing)
  • Claustrophobia or discomfort related to having enclosed equipment around the head
  • Unwillingness or inability to consume study diets or foods provided due to personal preference or food allergies/sensitivities
  • Unwillingness or inability to adhere to study exercise restrictions and prescriptions

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Ciência básica
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Active adults representative of overweight phenotype

Active adults representative of overweight phenotype will complete a 48h balance phase followed by two rounds of repeated 72h energy deficit exposure, each immediately followed by a 48h recovery phase.

Intervention consists of a 48 hour energy balance phase preceding two rounds of repeated 72 hour energy deficit exposure each immediately followed by a 48h recovery phase. Balance and recovery phases will meet 100% of baseline energy requirements. Energy deficit phases will include an approximate 60% energy deficit of total daily energy requirements achieved through both a reduction in dietary intake and increased energy expenditure through physical activity.

Comparador Ativo: Active adults representative of normal weight phenotype

Active adults representative of normal weight phenotype will complete a 48h balance phase followed by two rounds of repeated 72h energy deficit exposure, each immediately followed by a 48h recovery phase.

Intervention consists of a 48 hour energy balance phase preceding two rounds of repeated 72 hour energy deficit exposure each immediately followed by a 48h recovery phase. Balance and recovery phases will meet 100% of baseline energy requirements. Energy deficit phases will include an approximate 60% energy deficit of total daily energy requirements achieved through both a reduction in dietary intake and increased energy expenditure through physical activity.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Integrated muscle protein synthesis
Prazo: Days 1-13

deuterium oxide stable isotope

Days 1-13
Whole-body protein balance
Prazo: 24 hours

15N alanine stable isotope

24 hours
Iron Absorption
Prazo: 24 hours

57-Fe dissolved in water

24 hours

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Jess A Gwin Principal Investigator, PhD, United States Army Research Institute of Environmental Medicine

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

2 de maio de 2025

Conclusão Primária (Real)

10 de abril de 2026

Conclusão do estudo (Real)

10 de abril de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

14 de janeiro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

14 de janeiro de 2025

Primeira postagem (Real)

20 de janeiro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

9 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

4 de novembro de 2026

Última verificação

1 de maio de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 24-33HC
  • MO240019 (Número de outro subsídio/financiamento: Military Operational Medicine Research Program)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant data will not be shared.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever